Luis Reina, MD
Neurology · Lawton, OKNPI 1891891362
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,916 of the $5,883 with a category attached, or 83.6%. It is spread thinly across 33 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 270 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- AbbVie$637
- UCB, Inc.$473
- EMD Serono, Inc.$372
- SK Life Science, Inc.$318
- Biohaven Pharmaceutical Holding Company Ltd.$296
- plus $3K from 27 others
What the payments were for
- Travel & lodging$94316%
- Food & beverage$4,91684%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 6 | $1,082 |
| AbbVie(2 entities) | 25 | $637 |
| UCB, Inc. | 28 | $473 |
| EMD Serono, Inc. | 21 | $372 |
| SK Life Science, Inc. | 14 | $318 |
| Biohaven Pharmaceutical Holding Company Ltd. | 32 | $296 |
| Supernus Pharmaceuticals, Inc. | 18 | $273 |
| Teva Pharmaceuticals USA, Inc. | 11 | $242 |
| Eisai Inc. | 10 | $191 |
| AstraZeneca | 9 | $185 |
| Pfizer | 10 | $184 |
| Bristol Myers Squibb | 10 | $182 |
| Neurocrine Biosciences, Inc. | 9 | $179 |
| Argenx US, Inc. | 7 | $174 |
| Biogen | 6 | $142 |
| Novartis | 5 | $137 |
| Acadia Pharmaceuticals Inc | 7 | $130 |
| Lundbeck LLC | 6 | $113 |
| Amgen | 4 | $98 |
| Kyowa Kirin, Inc. | 4 | $70 |
| GE HealthCare | 5 | $60 |
| Lilly USA, LLC | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 7 | $45 |
| Corium, LLC | 2 | $43 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 2 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Neurelis, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$907
- NURTEC ODT$123
How this compares
$5,883 in reported general payments places this provider in the 65th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 20 | $197,796 |
| IngrezzaValbenazine Tosylate | 12 | $94,967 |
| XcopriCenobamate | 70 | $88,433 |
| Rufinamide | 69 | $81,006 |
| Aimovig AutoinjectorErenumab-Aooe | 89 | $78,723 |
| QuliptaAtogepant | 60 | $76,058 |
| Emgality PenGalcanezumab-Gnlm | 73 | $64,998 |
| NuplazidPimavanserin Tartrate | 12 | $61,135 |
| UbrelvyUbrogepant | 22 | $42,837 |
| Lacosamide | 273 | $28,956 |
| Nurtec OdtRimegepant Sulfate | 20 | $27,446 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 26 | $19,696 |
| Oxtellar XrOxcarbazepine | 13 | $17,204 |
| LamictalLamotrigine | 12 | $13,022 |
| RytaryCarbidopa/Levodopa | 19 | $8,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $637 | $118,89482 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $179 | $94,96712 claims |
| SK Life Science, Inc.Xcopri | $318 | $88,43370 claims |
| Acadia Pharmaceuticals IncNuplazid | $130 | $61,13512 claims |
| PfizerNurtec Odt, Dilantin | $184 | $30,30735 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $273 | $17,20413 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $25 | $11,04952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 152 neurology providers in Oklahoma.
Other neurology in Lawton
- Nabila ElzindLawton$16K
- Saurabh LalanLawton$15K
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Jaclyn DuvallTulsa$1.4M
- Gregory ConnorTulsa$444K
- Brett DeesNorman$420K
- Eduardo de SousaMoore$393K
- Tania ReynaTulsa$353K
- Marguerite ButcheeOklahoma City$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.